| Name | PureTech Health |
|---|---|
| Epic | PRTC |
| Isin | GB00BY2Z0H74 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 169.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £404.62 | Debt ratio | n/a |
| Shares in issue | 270.81 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -37.78 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -18 | 52-week high / low | 140.40p / 237.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | PureTech Health |
|---|---|
| Address | 8th Floor, 20 Farringdon Street, London, United Kingdom, EC4A 4AB |
| Telephone | |
| Website | http://www.puretechhealth.com |
| Director | Position |
|---|---|
| Mr Bharatt Chowrira | CEO |
| Dr. Robert Langer | Non-Executive Director |
| Mr H. Robert Horvitz | Non-Executive Director |
| Dr. Raju Kucherlapati | Interim Chairman |
| Ms Kiran Mazumdar Shaw | Independent Non-Executive Director |
| Dr. John LaMattina | Independent Non-Executive Director |
| Ms Sharon Barber-Lui | Independent Non-Executive Director |
| Assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 0.83 | 0.99 | 0.9 |
| Investments and other non-current assets | 261.04 | 397.18 | 530.16 |
| Total non-current assets | 316.45 | 444.2 | 575.65 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 33.97 | 18.86 | 8.34 |
| Cash and equivalents | 149.87 | 465.71 | 403.88 |
| Other current assets and asset held for resale | 2.12 | 17.24 | 2.12 |
| Total of all assets | 702.65 | 946.01 | 989.99 |
| Liabilities $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 96.89 | 226.13 | 180.92 |
| Long term liabilities | 58.17 | 135.72 | 155.53 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 155.06 | 361.86 | 336.45 |
| Net assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 547.59 | 584.15 | 653.54 |
| Equity $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 5.46 | 5.44 | 5.42 |
| Minority interests | 5.37 | -9.37 | -16.21 |
| Retained earnings | 149.52 | 199.87 | 260.43 |
| Share premium account | 289.62 | 289.3 | 288.98 |
| Total equity | 547.59 | 584.15 | 653.54 |
| Income $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -197.81 | -150.28 | -119.53 |
| Pre-tax profit | -92.78 | -58.95 | 18.97 |